Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2Na.86O.9Sb.21W.17H4N |
| Molecular Weight | 6685.06 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 2 |
SHOW SMILES / InChI
SMILES
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a++].[Na++].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[Sb+3].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6].[W+6]
InChI
InChIKey=HIMFWDDKEANLEL-UHFFFAOYSA-A
InChI=1S/17H3N.2Na.86O.9Sb.21W/h17*1H3;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/q;;;;;;;;;;;;;;;;;2*+2;86*-2;9*+3;21*+6/p+17
HPA-23 (ammonium-21-tungsto-9- antimoniate) inhibits retrovirus replication by inhibiting RNA-dependent DNA polymerases and thus could be effective in the treatment of HIV-1 infections and AIDS. HPA-23 inhibits nucleic acid polymerases in vitro and has antiviral activity both in vitro and in vivo. Furthermore, HPA-23 inhibits HIV-1 reverse transcriptase in vitro. Inhibition occurred when treatment with HPA-23 was started 18 to 24 h after infection in the plaque assay but no effect was seen when HPA 23 was added 48 h after virus inoculation. HPA-23 was concentrated in the lysosomes and localized in the macrophages of different tissues (thymus, spleen and bone marrow). By 1986, the National Academy of Science had concluded that no therapeutic benefits for persons infected with HIV could be attributed to HPA-23. It was subsequently abandoned as a treatment option.
Approval Year
Sample Use Guides
In vitro studies, in semi-solid agar, have shown an inhibitory effect of increasing concentrations of HPA-23 on the normal human granulocyte-macrophage progenitor cells colony and cluster formation. This effect is probably dose-dependent. An almost complete inhibition of colony formation was observed at doses of more than 20 ug/ml.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
7785
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
HPA-23
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
m6059
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | Merck Index | ||
|
C1378
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
J08H62IZC9
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
89899-81-0
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
